On August 8, 2025, after the market closed, C3 announced disappointing preliminary financial results for the first quarter of fiscal 2025. Specifically, C3 reported revenue which was below its prior guidance. C3’s CEO attributed the disappointing results to two main factors: 1) disruption from a complete restructuring of the company’s sales and services organization; and 2) his own health issues that prevented his active involvement in sales processes.
On this news, C3’s stock price fell over 20%, from a close of $22.13 on August 8, 2025, to close at $16.47 on August 11, 2025.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.